Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2002 1
2003 6
2004 4
2005 6
2006 17
2007 29
2008 43
2009 45
2010 47
2011 44
2012 43
2013 58
2014 51
2015 45
2016 46
2017 50
2018 42
2019 36
2020 34
2021 35
2022 42
2023 35
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

664 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.
Gómez-Revuelta M, Pelayo-Terán JM, Juncal-Ruiz M, Vázquez-Bourgon J, Suárez-Pinilla P, Romero-Jiménez R, Setién Suero E, Ayesa-Arriola R, Crespo-Facorro B. Gómez-Revuelta M, et al. Int J Neuropsychopharmacol. 2020 Apr 23;23(4):217-229. doi: 10.1093/ijnp/pyaa004. Int J Neuropsychopharmacol. 2020. PMID: 31974576 Free PMC article. Clinical Trial.
The aim of this study is to compare the clinical effectiveness of olanzapine, risperidone, haloperidol, aripiprazole, ziprasidone, and quetiapine in the treatment of first episode of psychosis at 3-year follow-up. ...A total of 376 first-episode drug-naive patients were ra …
The aim of this study is to compare the clinical effectiveness of olanzapine, risperidone, haloperidol, aripiprazole, ziprasidone, an …
Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis.
Terao I, Tsuge T, Endo K, Kodama W. Terao I, et al. J Affect Disord. 2024 Feb 1;346:49-56. doi: 10.1016/j.jad.2023.11.023. Epub 2023 Nov 8. J Affect Disord. 2024. PMID: 37949235 Review.
However, its clinical utility compared with intranasal esketamine and the other well-studied conventional pharmacological interventions (i.e., aripiprazole and lithium) as augmentative treatments for treatment-resistant unipolar depression in adults remains unclear. ...In …
However, its clinical utility compared with intranasal esketamine and the other well-studied conventional pharmacological interventions (i.e …
Aripiprazole for schizophrenia.
El-Sayeh HG, Morganti C. El-Sayeh HG, et al. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD004578. doi: 10.1002/14651858.CD004578.pub3. Cochrane Database Syst Rev. 2006. PMID: 16625607 Review.
OBJECTIVES: To evaluate the effects of aripiprazole for people with schizophrenia and schizophrenia-like psychoses. ...SELECTION CRITERIA: All clinical randomised trials comparing aripiprazole with placebo, typical or atypical antipsychotic drugs for schizophrenia a …
OBJECTIVES: To evaluate the effects of aripiprazole for people with schizophrenia and schizophrenia-like psychoses. ...SELECTION CRIT …
Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation).
Ostinelli EG, Jajawi S, Spyridi S, Sayal K, Jayaram MB. Ostinelli EG, et al. Cochrane Database Syst Rev. 2018 Jan 8;1(1):CD008074. doi: 10.1002/14651858.CD008074.pub2. Cochrane Database Syst Rev. 2018. PMID: 29308601 Free PMC article. Review.
BACKGROUND: People experiencing psychosis may become aggressive. Antipsychotics, such as aripiprazole in intramuscular form, can be used in such situations. OBJECTIVES: To evaluate the effects of intramuscular aripiprazole in the treatment of psychosis-induced aggre …
BACKGROUND: People experiencing psychosis may become aggressive. Antipsychotics, such as aripiprazole in intramuscular form, can be u …
Therapeutic Reference Range for Aripiprazole in Schizophrenia Revised: a Systematic Review and Metaanalysis.
Hart XM, Hiemke C, Eichentopf L, Lense XM, Clement HW, Conca A, Faltraco F, Florio V, Grüner J, Havemann-Reinecke U, Molden E, Paulzen M, Schoretsanitis G, Riemer TG, Gründer G. Hart XM, et al. Psychopharmacology (Berl). 2022 Nov;239(11):3377-3391. doi: 10.1007/s00213-022-06233-2. Epub 2022 Oct 5. Psychopharmacology (Berl). 2022. PMID: 36195732 Free PMC article. Review.
METHODS: The relevant literature was systematically searched and reviewed for aripiprazole oral and injectable formulations. Population-based concentration ranges were computed (N = 3,373) and pharmacokinetic influences investigated. ...We suggest a therapeutic reference r …
METHODS: The relevant literature was systematically searched and reviewed for aripiprazole oral and injectable formulations. Populati …
Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial.
Lenze EJ, Mulsant BH, Blumberger DM, Karp JF, Newcomer JW, Anderson SJ, Dew MA, Butters MA, Stack JA, Begley AE, Reynolds CF 3rd. Lenze EJ, et al. Lancet. 2015 Dec 12;386(10011):2404-12. doi: 10.1016/S0140-6736(15)00308-6. Epub 2015 Sep 27. Lancet. 2015. PMID: 26423182 Free PMC article. Clinical Trial.
FINDINGS: From July 20, 2009, to Dec 30, 2013, we recruited 468 eligible participants, 181 (39%) of whom did not remit and were randomly assigned to aripiprazole (n=91) or placebo (n=90). A greater proportion of participants in the aripiprazole group achieved remiss …
FINDINGS: From July 20, 2009, to Dec 30, 2013, we recruited 468 eligible participants, 181 (39%) of whom did not remit and were randomly ass …
Aripiprazole alone or in combination for acute mania.
Brown R, Taylor MJ, Geddes J. Brown R, et al. Cochrane Database Syst Rev. 2013 Dec 17;(12):CD005000. doi: 10.1002/14651858.CD005000.pub2. Cochrane Database Syst Rev. 2013. PMID: 24346956 Review.
Other objectives include reviewing the acceptability of treatment with aripiprazole, investigating the adverse effects of aripiprazole treatment, and determining overall mortality rates among those receiving aripiprazole treatment. ...Two studies compared …
Other objectives include reviewing the acceptability of treatment with aripiprazole, investigating the adverse effects of aripipra
A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder.
Harlin M, Yildirim M, Such P, Madera-McDonough J, Jan M, Jin N, Watkin S, Larsen F. Harlin M, et al. CNS Drugs. 2023 Apr;37(4):337-350. doi: 10.1007/s40263-023-00996-8. Epub 2023 Mar 24. CNS Drugs. 2023. PMID: 36961650 Free PMC article. Clinical Trial.
The objectives of this trial were to evaluate the safety and tolerability of Ari 2MRTU 960, and the similarity of aripiprazole plasma concentrations following administration of Ari 2MRTU 960 or aripiprazole once-monthly 400 mg (AOM 400), in adults with schizophrenia …
The objectives of this trial were to evaluate the safety and tolerability of Ari 2MRTU 960, and the similarity of aripiprazole plasma …
Optimal dose of aripiprazole for augmentation therapy of antidepressant-refractory depression: preliminary findings based on a systematic review and dose-effect meta-analysis.
Furukawa Y, Hamza T, Cipriani A, Furukawa TA, Salanti G, Ostinelli EG. Furukawa Y, et al. Br J Psychiatry. 2022 Aug;221(2):440-447. doi: 10.1192/bjp.2021.165. Br J Psychiatry. 2022. PMID: 35049482 Free article. Review.
BACKGROUND: Aripiprazole augmentation is proven effective for antidepressant-refractory depression, but its licensed dose range is wide and optimal dosage remains unclear. AIMS: To find the optimal dosage of aripiprazole augmentation. METHOD: Multiple electronic dat …
BACKGROUND: Aripiprazole augmentation is proven effective for antidepressant-refractory depression, but its licensed dose range is wi …
Aripiprazole for autism spectrum disorders (ASD).
Hirsch LE, Pringsheim T. Hirsch LE, et al. Cochrane Database Syst Rev. 2016 Jun 26;2016(6):CD009043. doi: 10.1002/14651858.CD009043.pub3. Cochrane Database Syst Rev. 2016. PMID: 27344135 Free PMC article. Review.
This review updates a previous Cochrane review on the safety and efficacy of aripiprazole for individuals with ASD, published in 2011 (Ching 2011). ...We searched for records published in 1990 or later, as this was the year aripiprazole became available. SELECTION C …
This review updates a previous Cochrane review on the safety and efficacy of aripiprazole for individuals with ASD, published in 2011 …
664 results